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Biomarker analysis of tumors from primary breast cancer patients has been 
commonplace for many years with analysis of estrogen receptor (ER) and HER2 
status being mandatory for guiding therapy with anti-endocrine or anti-HER2 
agents. As well as guiding adjuvant therapy these same markers, but few others 
so far, are used to guide treatment selection for metastatic disease; although they 
are increasingly often measured in metastatic biopsies their assessment in 
primary tumors remains the most frequent approach. Over recent years many 
multiparameter molecular tests have become available for breast cancer 
management. These are mainly aimed at establishing the risk of recurrence of 
patients with ER+ve disease who are due to receive standard endocrine therapy. 
Based on the prognosis of these patients, judgements can be made of the likely 
value of chemotherapy to improve that prognosis further. To date these 
prognostic tests have had no applicability in metastatic disease. 
 
One of the multiparameter tests, derives from the global gene expression 
profiling work of Perou and colleagues about 15 years ago and is used to identify 
the so-called intrinsic subtypes of breast cancer1,2.   The observation that the 
defined subtypes had prognostic significance2 drove the interest in their 
application in breast cancer management. Through a number of iterations the 
subtypes, when assessed using RNA profiling, are now most commonly based on 
the PAM-50 classifier of 50 genes that can be used to characterise tissue that has 
been subject to routine formalin fixation and paraffin embedding3.  The test is 
generally used to identify five major subtypes, Luminal A, Luminal B, HER2-
enriched (HER2E), Basal-like or Normal-like, according to the correlation of the 
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expression of the 50 genes with an archetypal expression profile for that 
subtype.  
 
An important aspect of the subtyping that appears to be poorly appreciated is 
that subtype is declared as the closest fit among the subtypes no matter how 
close or distant that fit is or how similar the fit is to a second subtype. In a recent 
study in which paired biopsies were available from 2 sets of untreated ER+ 
tumors, we noted a discordance of between 15 and 20% in the allocation of the 
subtype to Luminal A or B depending on which of the two biopsies was 
evaluated4.  Unsurprisingly, this discordance was more apparent when the 
correlation of the samples was closely similar with the archetypal Luminal A or B 
subtype. This issue is not exclusive to the luminal subtypes, although the Basal-
like subtype is generally clearly distinct.   
 
In the article by Prat et al in the current issue5,  the authors took the unusual 
approach of assessing the clinical importance of intrinsic subtyping of tumors 
from postmenopausal patients with advanced hormone receptor positive breast 
cancer that had previously been untreated in the metastatic context. The patients 
had participated in a randomized clinical trial of letrozole with or without 
lapatinib (study EGF30008) that was unusual in that it included both HER2+ve 
and HER2-ve patients despite lapatinib being widely considered as a HER2-
directed therapy6.    Successful intrinsic subtyping was achieved in 821 tumor 
samples from the 1286 patients in the trial. In the original report of the trial5,   
median progression-free survival (PFS) was increased from 3.0 months to 8.2 
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months by the addition of lapatinib in the 219 patients with HER2+ve disease 
but there was no improvement in PFS in the 952 patients with HER2-ve disease.  
 
The current report5 focuses largely on the prognostic importance of the 
subtyping in the HER2-ve population (a total of 644 patients in this substudy). As 
expected the majority (82%) were found to be Luminal (52% A and 30% B) in 
that population. Only 3% were identified as HER2E and 3% as Basal-like with 
12% being called Normal-like. Intrinsic subtype (in most cases based on the 
phenotype of the primary tumor) made a strong contribution to the Cox 
multivariable model for both PFS and overall survival (OS) with the hazard ratios 
for Luminal B versus Luminal A being 1.47 and 1.57, respectively. The features 
that most obviously distinguish Luminal B from Luminal A tumors are higher 
proliferation and greater frequency of progesterone receptor (PgR)-negativity. 
This has led to the proliferation marker Ki67 and/or PgR being the most 
frequently used markers to create immunohistochemical surrogates for 
separating Luminal A from B subtypes among ER+ve/HER2-ve tumors7,8.    As 
noted by Prat et al5 several earlier publications identified relationships between 
Ki67 and/or PgR expression in primary tumors and PFS after first line metastatic 
treatment9-11.   It is not clear from the paper by Prat et al5 whether features other 
than the expression of proliferation-related genes or of PgR are implicated in this 
relationship with PFS.  
 
Another key finding in the article by Prat et al5  is that in the small subgroup of 
patients with HER2E/HER2-ve tumors outcome was exceptionally poor: median 
PFS was only 4.7 months (95% CI: 2.7-10.8) and OS 16 months (95% CI: 10-NA) 
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which were 2.9-fold and 2.5-fold poorer, respectively, than in patients carrying 
Luminal A tumors. Of particular note, however, the HER2E/ HER2-ve tumors 
showed significant benefit from lapatinib treatment for which the interaction 
test was significant (univariate P=0.02, multivariate P=0.006) even though there 
were only 16 patients of this phenotype in the study. Median PFS was still only 
6.5 months in the group receiving lapatinib with letrozole but this compares 
with 2.6 months for those receiving letrozole alone. None of the other intrinsic 
subgroups of HER2-ve tumors showed benefit from lapatinib 
 
Any interpretation of this result requires a greater understanding of what types 
of tumor constitute the HER2E group particularly what types of HER2-ve tumors. 
In the original studies by Perou and colleagues, which included ER-ve as well as 
ER+ve tumors1,2, it was notable that ER+HER2+ tumors tended to segregate to 
the Luminal subtypes rather than HER2E. The Prat et al study deals with only 
ER+ve cases and this poses challenges to the normalization of data to allow 
accurate subtyping. Consistent with the earlier studies, only 29% of the HER2-
positive tumors were classified as HER2E with similar numbers being classified 
as Luminal A (27%) or Luminal B (29%). SO there are large numbers of cases 
that might be considered as enriched for HER2 expression but are not subtyped 
as HER2E. 
 
But why would some ER+ve/HER2-ve tumors be classified as HER2E when 
median levels of HER2 expression in them were no higher than in Luminal A 
HER2-ve tumors? What are the molecular features that lead to such tumors 
being described as HER2E if not HER2 itself? And why would they benefit from 
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added lapatinib? Examination of the heatmap showing the expression of genes 
for the tumors in the study (eFigure 2) is not illuminating: some of the 
HER2E/HER2-ve tumors cluster as part of an otherwise HER2E/HER2+ve group 
but most do not form a discrete group and are widely distributed across 
hierarchical clustering tree.  
 
Prat et al comment that the efficacy of lapatinib in this group might be due to 
inhibition of EGFR rather than HER2: despite lapatinib being regarded largely as 
a HER2-targeted agent nowadays it also has activity against EGFR12 and this was 
part of the rationale behind including HER2-ve cases in the EGF30008 study6.  
This was also part of reasoning for the inclusion of both HER2-positive and 
negative cases in a short-term presurgical study of lapatinib in patients with 
early breast cancer conducted by our group13.    In this we observed 27% 
suppression of the proliferation marker Ki67 in the HER2-ve group (n=72) which 
was statistically significant although less than that in the HER2+ve group (46% 
reduction, n=19). EGFR expression did not correlate with the antiproliferative 
response in the HER2-ve patients but mRNA levels of HER3 did. The HER3 
expression also correlated with higher HER2 transcript levels. Coombes et al14 
reported that 4/41 patients with HER2-ve breast cancer showed a >50% 
reduction in Ki67 in a similar study of short-term treatment with lapatinib: all 
four were HER3-positive. Heterodimerization of between HER3 and HER2 is 
known to enhance the kinase activity of HER2 (ref 15) and provides a plausible, 
though unproven, explanation for the impact of lapatinib in these HER2-ve 
tumors. HER3 is not included in the 50 genes of the PAM50 used for intrinsic 
subtyping so further interrogation of the molecular data from the Prat study 
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would be needed to determine if this interaction could similarly explain 
response in their HER2E/HER2-negative cases. 
 
The novel study by Prat et al5 of intrinsic subtyping in relation to progression of 
metastatic disease provided several provocative results. As with most other 
studies linking intrinsic subtype to clinical outcome, trying to understand the 
basis of the relationships inevitably leads us to try to disentangle the individual 
features that describe or are otherwise associated with the subtypes. 
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